Potassium channel modulators as anti-inflammatory agents

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 7, 2001, Pages 1137-1145

  Tanhehco, E J ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

BKCa; Immunosuppressant; Inflammation; Ischaemia reperfusion (I R) injury; KATP Kv1.3; Potassium (K+); T cell

Indexed keywords

1,2,4 THIADIAZINE DERIVATIVE; 2 CYANO 1 (4 CYANOPHENYL) 3 (1,2,2 TRIMETHYLPROPYL)GUANIDINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM); AMYLOID PRECURSOR PROTEIN; ANTIINFLAMMATORY AGENT; APRIKALIM; BENZOPYRAN DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; CALCIUM ION; CROMAKALIM; DIAZOXIDE; FORMAMIDE DERIVATIVE; GUANIDINE DERIVATIVE; HEAT SHOCK PROTEIN 70; MINOXIDIL SULFATE; N (4 CHLOROPHENYL) N' CYANO N'' (6 CYANO 3,4 DIHYDRO 3 HYDROXY 2,2 DIMETHYL 2H 1 BENZOPYRAN 4 YL)GUANIDINE; PHOSPHORYL LIPID A; PINACIDIL; POTASSIUM CHANNEL; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL STIMULATING AGENT; POTASSIUM ION; PROTEIN C FOS; PROTEIN C JUN; PYRIMIDINE DERIVATIVE; SDZ 217 744; SULFONYLUREA DERIVATIVE; THIADIAZINE DERIVATIVE; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CANCER; CARDIOSELECTIVITY; CARDIOVASCULAR DISEASE; CELL ACTIVITY; CELL MEMBRANE DEPOLARIZATION; CELL TYPE; CENTRAL NERVOUS SYSTEM DISEASE; CHANNEL GATING; CHICKEN; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TARGETING; HEART PROTECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; ISCHEMIA; MUSCLE CELL; NONHUMAN; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TACHYCARDIA; TISSUE INJURY; TISSUE SPECIFICITY;

EID: 0034931509     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.7.1137     Document Type: Review

References (75)

1. Potassium channel activation: A potential therapeutic approach?
2. + channels in the rabbit
3. + channel
4. ATP-sensitive potassium channels in smooth muscle cells from guinea pig urinary bladder
5. Topical minoxidil. A preliminary review of its pharmacodynamics properties and therapeutic efficacy in alopecia areata and alopecia androgenetics
6. Potassium channel activator drugs: Mechanism of action, pharmacological properties and therapeutic potential
7. Comparison of the effects of vasodilator drugs on intraocular pressure and vascular relaxation
8. + channels in pancreatic, cardiac, and vascular smooth muscle cells
9. Association and stoichiometry of KATP channel subunits
10. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium
11. Neuroprotection from ischemic brain injury by hypoxic preconditioning in the neonatal rat
12. Liver ischemic preconditioning is mediated by the inhibitory action of nitric oxide on endothelin
13. Protection against infarction afforded by preconditioning is mediated by the A1 adenosine receptors in rabbit heart
14. An irreversible A1-selective adenosine agonist preconditions rabbit heart
15. Preconditioning protects the ischemic rabbit heart by protein kinase C activation
16. Superoxide dismutase and N-2-mercaptopropionyl glycine attenuate infarct size limitation effect of ischemic preconditioning in the rabbit
17. Preconditioning against myocardial dysfunction after ischemia and reperfusion by an alpha 1-adrenergic mechanism
18. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs
19. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide
20. + channels: Possible mechanism of cardioprotection
21. Mitochondrial ATP-dependent potassium channels: Novel effectors of cardioprotection?
22. Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448
23. Direct preconditioning of cardiac myocytes via opioid receptors and KATP channels
24. KATP channels mediate late preconditioning against infarction produced by monophosphoryl lipid A
25. Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate
26. Activation of mitochondrial ATP-sensitive K(+) channel for cardiac protection against ischemic injury is dependent on protein kinase C activity
27. Opening mitochondrial KATP in the heart - What happens, and what does not happen
28. + channel openers prevent global ischemia-induced expression of c-fos, c-jun, heat shock protein, and amyloid beta-protein precursor genes and neuronal death in rat hippocampus
29. Preconditioning reduces tissue complement gene expression in the rabbit isolated heart
30. Preconditioning reduces tissue complement gene expression in vivo
31. Potassium channels and preconditioning of isolated rabbit cardiomyocytes: Effects of glyburide and pinacidil
32. Adenosine A1 receptors, KATP channels, and ischemic preconditioning in dogs
33. KATP channels contribute to the cardioprotection of preconditioning independent of anaesthetics in rabbit hearts
34. Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine
35. Pharmacology and structure-activity relationships for KATP modulators: Tissue-selective KATP openers
36. Differential effects of cromakalim on pancreatic vascular resistance and insulin secretion in vitro
37. Pharmacology of the potassium channel openers
38. Potassium channel openers: Airway pharmacology and clinical possibilities in asthma
39. Potassium channel activators and bronchial asthma
40. KATP channel openers for the treatment of airways hyperreactivity
41. Attenuation of nocturnal asthma by cromakalim
42. Additive effects of late preconditioning produced by monophosphoryl lipid A and the early preconditioning mediated by adenosine receptors and KATP channel
43. + - Channels of cardiomyocytes by endogenous cardiopeptides
44. Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation
45. + channels depolarize human T lymphocytes: Mechanism of the antiproliferative effect of charybdotoxin
46. Human T-cell Kv1.3 potassium channel blockers: New strategies for immunosuppression
47. Voltage-gated potassium channel genes
48. + channel revealed by the NMR-derived structures of scorpion toxins
49. + channels in open, closed and inactivated conformations
50. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo
51. + channels. Basis for high-affinity toxin interactions and pharmacology
52. + channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation
53. An essential binding surface for ShK toxin interaction with rat brain potassium channels
54. On the convergent evolution of animal toxins. Conservation of a diad of functional residues in potassium channel-blocking toxins with unrelated structures
55. A potassium-channel toxin from the sea anemone Bunodosoma granulifera, an inhibitor of Kv1 channels. Revision of the amino acid sequence, disulfide-bridge assignment, chemical synthesis, and biological activity
56. 22, a potent Kv1.3-specific immunosuppressive polypeptide
57. Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels
58. Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3
59. UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation
60. Potassium channel openers as potential therapeutic weapons in ion channel disease
61. Purification and reconstitution of the high-conductance, calcium activated potassium channel from tracheal smooth muscle
62. Subunit composition of the high-conductance, calcium activated potassium channel from smooth muscle, a representative of the mSlo and slowpoke family of potassium channels
63. Mechanism of the maxi-K channel activation by dehydrosoyasaponin-I
64. L-735,334, a novel sesquiterpenoid potassium channel-agonist from Trichoderma virens
65. + chanels
66. The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel
67. Potassium channel activators protect the N-methyl-D-aspartate-induced cerebral vascular dilation after combined hypoxia and ischemia in piglets
68. Inhibition by fenamates of calcium influx and proliferation of human lymphocytes
69. Pharmacological control of human polymorphonuclear leukocyte degranulation by fenamates and inhibitors of receptor-mediated calcium entry and protein kinase C
70. Fenamates protect neurons against ischemic and excitotoxic injury in chick embryo retina
71. Effects of prostaglandin antagonist phloretin derivatives on mouse ear edema induced with different skin irritants
72. Action of niflumic acid on evoked and spontaneous calcium-activated chloride and potassium currents in smooth muscle cells from rabbit portal vein
73. Stilbenes and fenamates rescue the loss of I(KS) channel function induced by an LQT5 mutation and other IsK mutants
74. Effect of activation on adhesion of flowing neutrophils to cultured endothelium: Time course and inhibition by a calcium channel blocker (nitrendipine)
75. Actions of pinacidil at a reduced potassium concentration: A direct cardiac effect possibly involving the ATP-dependent potassium channel